Indoco Remedies
NSE: INDOCO · Pharmaceuticals
Snapshot
Unlock Indoco Remedies's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Indoco Remedies is an Indian pharmaceutical company engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients. Its diverse portfolio spans therapeutic areas including respiratory, stomatological, gastrointestinal, and ophthalmic products, alongside specialized analytical and engineering services.
Business Model
The company generates revenue through the sale of branded pharmaceutical formulations and APIs across domestic and international markets. Additionally, it leverages its technical expertise to provide contract analytical services and specialized engineering solutions for the pharmaceutical industry.
- Founded:1945
Growth Outlook
Growth is driven by the expansion of its therapeutic product range and the provision of high-value analytical and project engineering services. The company continues to target a broad spectrum of medical specialists to increase its market penetration.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality standards and inspections by international health authorities like the USFDA.
- Pricing Pressure. Government-mandated price controls on essential medicines in India can significantly impact profit margins.
- Competition. The highly fragmented Indian pharmaceutical market presents intense competition from both domestic generic players and multinational corporations.
- Supply Chain Volatility. Fluctuations in the cost and availability of raw materials and active pharmaceutical ingredients can disrupt production schedules.
Start your research today
Unlock AI insights, financials, peers and live data on Indoco Remedies and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,909 Cr
TTM · consolidated
NET PROFIT
₹32 Cr
TTM · consolidated
EPS
₹3.43
TTM · consolidated
RETURN ON EQUITY
3.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
10.9%
TTM · consolidated
P/E
62.9×
Q2 FY27 · consolidated
EV/EBITDA
16.5x
Q2 FY27 · consolidated
EBITDA MARGIN
9.1%
TTM · consolidated
NET PROFIT MARGIN
3.7%
Q2 FY27 · consolidated
DEBT TO EQUITY
1.0x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Indoco RemediesINDOCO | ₹1,923 Cr | 62.9× | 16.48 | 10.8% | 9.1% | 3.2% | 10.9% | -22.8% |
Beta Drugs LtdBETA | ₹2,000 Cr | — | — | — | 13.0% | — | — | -4.3% |
Hester Biosciences LimitedHESTERBIO | ₹1,947 Cr | 14.2× | 22.31 | 4.1% | 29.4% | 40.6% | 30.8% | +42.1% |
Panacea BiotecPANACEABIO | ₹1,919 Cr | -282.5× | 106.74 | 10.3% | 2.6% | -1.1% | -0.4% | -25.2% |
Syncom Formulations (India) LimitedSYNCOMF | ₹1,809 Cr | 20.4× | 14.92 | 0.4% | 24.3% | 22.6% | 29.1% | +16.8% |
Windlas BiotechWINDLAS | ₹1,808 Cr | 28.8× | 14.99 | 18.5% | 13.0% | 12.2% | 16.8% | -3.8% |
As of Q2 FY27
Financials
Indoco Remedies
NSE: INDOCO · Pharmaceuticals
Snapshot
Unlock Indoco Remedies's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Indoco Remedies is an Indian pharmaceutical company engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients. Its diverse portfolio spans therapeutic areas including respiratory, stomatological, gastrointestinal, and ophthalmic products, alongside specialized analytical and engineering services.
Business Model
The company generates revenue through the sale of branded pharmaceutical formulations and APIs across domestic and international markets. Additionally, it leverages its technical expertise to provide contract analytical services and specialized engineering solutions for the pharmaceutical industry.
- Founded:1945
Growth Outlook
Growth is driven by the expansion of its therapeutic product range and the provision of high-value analytical and project engineering services. The company continues to target a broad spectrum of medical specialists to increase its market penetration.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality standards and inspections by international health authorities like the USFDA.
- Pricing Pressure. Government-mandated price controls on essential medicines in India can significantly impact profit margins.
- Competition. The highly fragmented Indian pharmaceutical market presents intense competition from both domestic generic players and multinational corporations.
- Supply Chain Volatility. Fluctuations in the cost and availability of raw materials and active pharmaceutical ingredients can disrupt production schedules.
Start your research today
Unlock AI insights, financials, peers and live data on Indoco Remedies and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,909 Cr
TTM · consolidated
NET PROFIT
₹32 Cr
TTM · consolidated
EPS
₹3.43
TTM · consolidated
RETURN ON EQUITY
3.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
10.9%
TTM · consolidated
P/E
62.9x
Q2 FY27 · consolidated
EV/EBITDA
16.5x
Q2 FY27 · consolidated
EBITDA MARGIN
9.1%
TTM · consolidated
NET PROFIT MARGIN
3.7%
Q2 FY27 · consolidated
DEBT TO EQUITY
1.0x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
As of Q2 FY27